Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DK-233 (rifampicin) bioequivalence study
jRCT1080223619Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of rifampicin in Tuberculosis (TB) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Bioequivalence of DK-233 150 mg capsules and DK-233 20 mg/mL syrup.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on jRCT1080223619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223619.